MedTrace Logo

Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer

NCT03172624 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2025-12-18

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to find out what effects, good and/or bad, treatment with two drugs called nivolumab and ipilimumab have on the participant and salivary cancer.

Conditions

  • Salivary Gland Cancer

Interventions

DRUG

Nivolumab

nivolumab 3 mg/kg every 2 weeks

DRUG

Ipilimumab

ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks)

Sponsors & Collaborators

Principal Investigators

  • Alan Ho, MD, PhD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-26
Primary Completion
2024-12-18
Completion
2024-12-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03172624 on ClinicalTrials.gov